查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1534411

急性细菌性皮肤和结构性感染疾病的全球市场：市场规模、份额、趋势分析、机会、预测，2019-2030

Acute Bacterial Skin and Skin Structure Infections Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019-2030, Segmented By Type of Infection; By Route of Administration; By Distribution Channel; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到2030年，全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场规模将达到235亿美元，以2.4倍的复合年增长率快速扩张。

由于ABSSSI盛行率不断增加、抗生素抗药性、治疗方案的进步、医疗保健成本的上升和宣导活动等，全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场正在以显着的速度蓬勃发展。 Masu。

该报告估计2023年全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场以金额为准为96.5亿美元。 BlueWeave 预测，在 2024 年至 2030 年的预测期内，全球急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 市场规模将以 10.55% 的复合年增长率增长，到 2030 年将达到 234.9 亿美元。由于製药和生物製药公司的意识增强和研发活动的增加，全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场正在显着成长。引起这些感染疾病的常见细菌包括化脓性链球菌和金黄色葡萄球菌，抗 MRSA 药物是一个重要的新兴概念。管道开拓、研发支出和药物核准预计将推动市场。 Melinta Therapeutics 等主要市场参与者也推出了醣肽抗生素 KIMYRSA 等新产品和活动。预计这些因素将在预测期内推动市场。

机会－诊断和治疗的技术进步

诊断工具和治疗方法的最新技术创新正在改变全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场的格局。先进的影像技术和快速诊断测试正在增强早期检测，从而实现及时干预并改善患者的治疗结果。此外，新抗生素的开发和抗生素抗药性菌株的治疗方法正在解决以前未满足的医疗需求。这些技术进步不仅减少了住院时间和医疗费用，也扩大了全球市场范围。因此，由于医疗技术的不断进步，ABSSSI 的全球市场有望大幅成长。

地缘政治紧张局势加剧对全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场的影响

不断升级的地缘政治紧张局势正在对全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场造成严重破坏。供应链的中断，特别是抗生素和医疗用品的供应链中断，会影响病患照护和治疗效果。政治不稳定和经济制裁也会扰乱药品的生产和分配，导致药品短缺和成本增加。国际合作下降和外交关係紧张可能会阻碍研发工作。

急性细菌性皮肤和皮肤结构感染疾病的全球市场 (ABSSSI)

全球急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 市场 – 按分销管道

按分销管道划分，全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场分为医院药房、零售药房和线上药房部分。医院药房部门因其有效管理复杂感染疾病、及时提供所需药物以及提供先进医疗基础设施的能力而受到认可，特别是在需要即时和重症监护的医院环境中，我们在全球ABSSSI 市场中占据主导地位。

竞争格局

全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场竞争激烈。该市场的主要企业包括辉瑞、默克、艾伯维、罗氏、葛兰素史克、强生、礼来公司、诺华、赛诺菲、阿斯特捷利康、梯瓦製药工业有限公司和迈兰NV。这些公司正在增加对感染疾病活动、併购、合资、联盟、授权合约的投资，我们正在使用各种策略，包括发布新产品和新剂量。

该报告的详细分析提供了有关全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场的成长潜力、未来趋势和统计数据的资讯。我们也研究了推动市场总规模预测的因素。该报告致力于提供全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场的最新技术趋势以及行业见解，以帮助决策者做出明智的策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第三章全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场分析

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 抗生素抗药性的蔓延
      • 高龄化社会
      • 侵入性医疗程序的增加
      • 提高对 ABSSSI 的认识
    • 抑制因素
      • 治疗费用上涨
      • 有效抗生素的供应有限
    • 机会
      • 诊断和治疗技术进步
      • 专注新兴市场
    • 任务
      • 抗生素的不当使​​用和自我药疗
      • 缺乏卫生意识和习惯
  • 科技进步/最新趋势
  • 法律规范
  • 波特五力分析

第四章全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场：行销策略

第五章全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场：区域分析

  • 急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 全球市场，区域分析，2023 年
  • 全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场，市场吸引力分析，2024-2030

第六章急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）的全球市场概述

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按感染类型
      • 院内ABSSI
      • 社区获得性 ABSSI
    • 依给药途径
      • 口服
      • 胃肠外的
      • 话题
    • 按分销管道
      • 医院药房
      • 零售药房
      • 网路药房
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东/非洲

第七章北美急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场

第八章欧洲急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场

第九章亚太地区急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场

第十章拉丁美洲急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场

第十一章中东和非洲急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场

第十二章竞争格局

  • 主要参与者及其产品列表
  • 急性细菌性皮肤和皮肤结构感染疾病(ABSSSI) 全球公司市场占有率分析，2023 年
  • 透过管理参数进行竞争基准化分析
  • 重大策略发展（合併、收购、联盟等）

第十三章地缘政治紧张局势加剧对全球急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）市场的影响

第十四章 公司简介

  • Pfizer
  • Merck &Co.
  • AbbVie
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline
  • Johnson &Johnson
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi SA
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV
  • 其他主要企业

第十五章 主要战略建议

第十六章调查方法

简介目录
Product Code: BWC24485

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Size Zooming 2.4X at Stellar CAGR to Touch USD 23.5 Billion by 2030

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is flourishing at a significant growth rate due to increasing ABSSSI incidence rates, antibiotic resistance, advancements in treatment options, and rising healthcare expenditure and awareness initiatives.

BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size by value at USD 9.65 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size to expand at a CAGR of 10.55% reaching a value of USD 23.49 billion in 2030. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is growing at a significant rate due to increasing awareness and R&D activities by pharmaceutical and biopharmaceutical companies. Common bacteria causing these infections include Streptococcus pyogenes and Staphylococcus aureus, with anti-MRSA drugs being a crucial emerging concept. Pipeline development, R&D expenditure, and drug approvals are expected to drive the market. Key market players, such as Melinta Therapeutics, are also launching new products and activities, such as KIMYRSA, a lipoglycopeptide antibiotic. These factors are expected to drive the market during the forecast period.

Opportunity - Technological advancements in diagnostics and treatment

Recent innovations in diagnostic tools and treatment modalities are revolutionizing the landscape of Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market. Advanced imaging techniques and rapid diagnostic tests are enhancing early detection, leading to prompt interventions and improved patient outcomes. Moreover, the development of novel antibiotics and therapies tailored to antibiotic-resistant strains is addressing previously unmet medical needs. These technological strides are not only reducing hospital stays and healthcare costs but also expanding the market scope globally. As a result, Global ABSSSI Market is poised for substantial growth driven by continuous advancements in medical technology.

Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

Intensifying geopolitical tensions are causing significant disruptions in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. Disruptions in supply chains, particularly for antibiotics and medical supplies, hinder patient care and treatment efficacy. Political instability and economic sanctions can also hinder pharmaceutical manufacturing and distribution, leading to drug shortages and increased costs. Reduced international collaboration and strained diplomatic relations can stifle research and development efforts.

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - By Distribution Channel

Based on distribution channel, Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The hospital pharmacies segment dominates the Global ABSSSI Market due to their ability to manage complex infections effectively, provide timely access to necessary medications, and offer advanced healthcare infrastructure, particularly in hospital settings where immediate and intensive care is required.

Competitive Landscape

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is fiercely competitive. Major companies in the market include Pfizer, Merck & Co., AbbVie, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, and Mylan N.V. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and dose releases to further strengthen their position in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising Prevalence of Antibiotic Resistance
      • 3.2.1.2. Aging Population
      • 3.2.1.3. Increase in Invasive Medical Procedures
      • 3.2.1.4. Growing Awareness of ABSSSI
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost of Treatment
      • 3.2.2.2. Limited Availability of Effective Antibiotics
    • 3.2.3. Opportunities
      • 3.2.3.1. Technological Advancements in Diagnostics and Treatment
      • 3.2.3.2. Focus on Emerging Markets
    • 3.2.4. Challenges
      • 3.2.4.1. Improper Antibiotic Use and Self-Medication
      • 3.2.4.2. Lack of Awareness and Hygiene Practices
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Marketing Strategies

5. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Geographical Analysis

  • 5.1. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, Geographical Analysis, 2023
  • 5.2. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, Market Attractiveness Analysis, 2024-2030

6. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Overview

  • 6.1. Market Size & Forecast, 2019-2030
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Infection
      • 6.2.1.1. Hospital-acquired ABSSI
      • 6.2.1.2. Community-acquired ABSSI
    • 6.2.2. By Route of Administration
      • 6.2.2.1. Oral
      • 6.2.2.2. ParentaL
      • 6.2.2.3. Topical
    • 6.2.3. By Distribution Channel
      • 6.2.3.1. Hospital Pharmacies
      • 6.2.3.2. Retail Pharmacies
      • 6.2.3.3. Online Pharmacies
    • 6.2.4. By Region
      • 6.2.4.1. North America
      • 6.2.4.2. Europe
      • 6.2.4.3. Asia Pacific (APAC)
      • 6.2.4.4. Latin America (LATAM)
      • 6.2.4.5. Middle East and Africa (MEA)

7. North America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Infection
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. United States
      • 7.2.4.1.1. By Type of Infection
      • 7.2.4.1.2. By Route of Administration
      • 7.2.4.1.3. By Distribution Channel
      • 7.2.4.2. Canada
      • 7.2.4.2.1. By Type of Infection
      • 7.2.4.2.2. By Route of Administration
      • 7.2.4.2.3. By Distribution Channel

8. Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Infection
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. Germany
      • 8.2.4.1.1. By Type of Infection
      • 8.2.4.1.2. By Route of Administration
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. United Kingdom
      • 8.2.4.2.1. By Type of Infection
      • 8.2.4.2.2. By Route of Administration
      • 8.2.4.2.3. By Distribution Channel
      • 8.2.4.3. Italy
      • 8.2.4.3.1. By Type of Infection
      • 8.2.4.3.2. By Route of Administration
      • 8.2.4.3.3. By Distribution Channel
      • 8.2.4.4. France
      • 8.2.4.4.1. By Type of Infection
      • 8.2.4.4.2. By Route of Administration
      • 8.2.4.4.3. By Distribution Channel
      • 8.2.4.5. Spain
      • 8.2.4.5.1. By Type of Infection
      • 8.2.4.5.2. By Route of Administration
      • 8.2.4.5.3. By Distribution Channel
      • 8.2.4.6. Belgium
      • 8.2.4.6.1. By Type of Infection
      • 8.2.4.6.2. By Route of Administration
      • 8.2.4.6.3. By Distribution Channel
      • 8.2.4.7. Russia
      • 8.2.4.7.1. By Type of Infection
      • 8.2.4.7.2. By Route of Administration
      • 8.2.4.7.3. By Distribution Channel
      • 8.2.4.8. The Netherlands
      • 8.2.4.8.1. By Type of Infection
      • 8.2.4.8.2. By Route of Administration
      • 8.2.4.8.3. By Distribution Channel
      • 8.2.4.9. Rest of Europe
      • 8.2.4.9.1. By Type of Infection
      • 8.2.4.9.2. By Route of Administration
      • 8.2.4.9.3. By Distribution Channel

9. Asia Pacific Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Infection
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. China
      • 9.2.4.1.1. By Type of Infection
      • 9.2.4.1.2. By Route of Administration
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. India
      • 9.2.4.2.1. By Type of Infection
      • 9.2.4.2.2. By Route of Administration
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Japan
      • 9.2.4.3.1. By Type of Infection
      • 9.2.4.3.2. By Route of Administration
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. South Korea
      • 9.2.4.4.1. By Type of Infection
      • 9.2.4.4.2. By Route of Administration
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. Australia & New Zealand
      • 9.2.4.5.1. By Type of Infection
      • 9.2.4.5.2. By Route of Administration
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Indonesia
      • 9.2.4.6.1. By Type of Infection
      • 9.2.4.6.2. By Route of Administration
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Malaysia
      • 9.2.4.7.1. By Type of Infection
      • 9.2.4.7.2. By Route of Administration
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. Singapore
      • 9.2.4.8.1. By Type of Infection
      • 9.2.4.8.2. By Route of Administration
      • 9.2.4.8.3. By Distribution Channel
      • 9.2.4.9. Vietnam
      • 9.2.4.9.1. By Type of Infection
      • 9.2.4.9.2. By Route of Administration
      • 9.2.4.9.3. By Distribution Channel
      • 9.2.4.10. Rest of APAC
      • 9.2.4.10.1. By Type of Infection
      • 9.2.4.10.2. By Route of Administration
      • 9.2.4.10.3. By Distribution Channel

10. Latin America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Infection
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. Brazil
      • 10.2.4.1.1. By Type of Infection
      • 10.2.4.1.2. By Route of Administration
      • 10.2.4.1.3. By Distribution Channel
      • 10.2.4.2. Mexico
      • 10.2.4.2.1. By Type of Infection
      • 10.2.4.2.2. By Route of Administration
      • 10.2.4.2.3. By Distribution Channel
      • 10.2.4.3. Argentina
      • 10.2.4.3.1. By Type of Infection
      • 10.2.4.3.2. By Route of Administration
      • 10.2.4.3.3. By Distribution Channel
      • 10.2.4.4. Peru
      • 10.2.4.4.1. By Type of Infection
      • 10.2.4.4.2. By Route of Administration
      • 10.2.4.4.3. By Distribution Channel
      • 10.2.4.5. Rest of LATAM
      • 10.2.4.5.1. By Type of Infection
      • 10.2.4.5.2. By Route of Administration
      • 10.2.4.5.3. By Distribution Channel

11. Middle East & Africa Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Million)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type of Infection
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
      • 11.2.4.1. Saudi Arabia
      • 11.2.4.1.1. By Type of Infection
      • 11.2.4.1.2. By Route of Administration
      • 11.2.4.1.3. By Distribution Channel
      • 11.2.4.2. UAE
      • 11.2.4.2.1. By Type of Infection
      • 11.2.4.2.2. By Route of Administration
      • 11.2.4.2.3. By Distribution Channel
      • 11.2.4.3. Qatar
      • 11.2.4.3.1. By Type of Infection
      • 11.2.4.3.2. By Route of Administration
      • 11.2.4.3.3. By Distribution Channel
      • 11.2.4.4. Kuwait
      • 11.2.4.4.1. By Type of Infection
      • 11.2.4.4.2. By Route of Administration
      • 11.2.4.4.3. By Distribution Channel
      • 11.2.4.5. South Africa
      • 11.2.4.5.1. By Type of Infection
      • 11.2.4.5.2. By Route of Administration
      • 11.2.4.5.3. By Distribution Channel
      • 11.2.4.6. Nigeria
      • 11.2.4.6.1. By Type of Infection
      • 11.2.4.6.2. By Route of Administration
      • 11.2.4.6.3. By Distribution Channel
      • 11.2.4.7. Algeria
      • 11.2.4.7.1. By Type of Infection
      • 11.2.4.7.2. By Route of Administration
      • 11.2.4.7.3. By Distribution Channel
      • 11.2.4.8. Rest of MEA
      • 11.2.4.8.1. By Type of Infection
      • 11.2.4.8.2. By Route of Administration
      • 11.2.4.8.3. By Distribution Channel

12. Competitive Landscape

  • 12.1. List of Key Players and Their Offerings
  • 12.2. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Company Market Share Analysis, 2023
  • 12.3. Competitive Benchmarking, By Operating Parameters
  • 12.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

13. Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market

14. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 14.1. Pfizer
  • 14.2. Merck & Co.
  • 14.3. AbbVie
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. GlaxoSmithKline
  • 14.6. Johnson & Johnson
  • 14.7. Eli Lilly and Company
  • 14.8. Novartis AG
  • 14.9. Sanofi S.A.
  • 14.10. AstraZeneca PLC
  • 14.11. Teva Pharmaceutical Industries Ltd
  • 14.12. Mylan N.V.
  • 14.13. Other Prominent Players

15. Key Strategic Recommendations

16. Research Methodology

  • 16.1. Qualitative Research
    • 16.1.1. Primary & Secondary Research
  • 16.2. Quantitative Research
  • 16.3. Market Breakdown & Data Triangulation
    • 16.3.1. Secondary Research
    • 16.3.2. Primary Research
  • 16.4. Breakdown of Primary Research Respondents, By Region
  • 16.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable